Analysis on the clinical efficacy and safety of venetoclax combined with azacitidine and donor lymphocyte infu-sion in treatment of the relapse of myeloid malignancies after allogeneic hematopoietic stem cell transplantation

SHI Ling-ling; WU Mei-qing; LIU Lian-jin

doi:10.3969/j.issn.1674-3806.2023.11.06

Home>Articles>Analysis on the clinical efficacy and safety of venetoclax combined with azacitidine and donor lymphocyte infu-sion in treatment of the relapse of myeloid malignancies after allogeneic hematopoietic stem cell transplantation

DOI: 10.3969/j.issn.1674-3806.2023.11.06

Analysis on the clinical efficacy and safety of venetoclax combined with azacitidine and donor lymphocyte infu-sion in treatment of the relapse of myeloid malignancies after allogeneic hematopoietic stem cell transplantation

SHI Ling-ling

WU Mei-qing

LIU Lian-jin

Keywords：Allogeneic hematopoietic stem cell transplantation(allo-HSCT)RelapseMyeloid malig-nanciesVenetoclaxAzacitidineDonor lymphocyte infusion

Publication Date：2023-11-28

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：6( 1130-1135 )

Chinese Journal of New Clinical Medicine

ISTIC

ISSN：1674-3806

Year, Vol.(Issue)：2023,16(11)